Erik Engel

565 total citations
14 papers, 232 citations indexed

About

Erik Engel is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Erik Engel has authored 14 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Erik Engel's work include Chronic Lymphocytic Leukemia Research (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Erik Engel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Erik Engel collaborates with scholars based in Germany, Austria and United States. Erik Engel's co-authors include Ferdy J. Lejeune, Wolfgang Tilgen, Christian Kennes, Dirk Arnold, M. van Glabbeke, M.A. Lentz, Norbert Marschner, Mathias Rummel, Richard Greil and Friederike Braig and has published in prestigious journals such as Blood, Oncotarget and Breast Cancer Research and Treatment.

In The Last Decade

Erik Engel

14 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Engel Germany	7	133	66	61	54	49	14	232
Bogumiła Ciseł Poland	9	80 0.6×	61 0.9×	40 0.7×	52 1.0×	111 2.3×	17	267
Adalgisa Condoluci Switzerland	10	74 0.6×	96 1.5×	106 1.7×	48 0.9×	47 1.0×	20	245
S. Lasserre Switzerland	7	257 1.9×	38 0.6×	69 1.1×	21 0.4×	88 1.8×	9	323
Jonathan Moreira United States	7	64 0.5×	122 1.8×	111 1.8×	55 1.0×	50 1.0×	16	248
Shehara Mendis Australia	6	145 1.1×	26 0.4×	52 0.9×	38 0.7×	89 1.8×	28	222
Yehuda E. Deutsch United States	8	103 0.8×	27 0.4×	44 0.7×	72 1.3×	19 0.4×	23	242
Ju‐Hee Bang South Korea	11	261 2.0×	59 0.9×	43 0.7×	79 1.5×	83 1.7×	39	385
Yuxin Chu China	9	136 1.0×	18 0.3×	28 0.5×	71 1.3×	112 2.3×	27	286
A. Astone Italy	9	233 1.8×	13 0.2×	57 0.9×	52 1.0×	82 1.7×	22	336
Weiying Gu China	10	76 0.6×	28 0.4×	55 0.9×	95 1.8×	20 0.4×	35	247

Countries citing papers authored by Erik Engel

Since Specialization

Citations

This map shows the geographic impact of Erik Engel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Engel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Engel more than expected).

Fields of papers citing papers by Erik Engel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Engel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Engel. The network helps show where Erik Engel may publish in the future.

Co-authorship network of co-authors of Erik Engel

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Engel. A scholar is included among the top collaborators of Erik Engel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Engel. Erik Engel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Engel, Erik, et al.. (2021). Virtual Termination amid COVID-19: Strategies for School Social Work Interns and Field Instructors. Children & Schools. 43(4). 216–223. 1 indexed citations

Rummel, Mathias, Christian Lerchenmüller, Manfred Hensel, et al.. (2019). Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 134(Supplement_1). 343–343. 35 indexed citations

Fietz, Thomas, et al.. (2017). Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study. Breast Cancer Research and Treatment. 167(2). 567–578. 15 indexed citations

Engel, Erik, et al.. (2017). Bénin: vers une transformationrurale inclusive et durable. edoc Publication server (Humboldt University of Berlin). 1 indexed citations

Marschner, Norbert, et al.. (2015). Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study. Clinical Epidemiology. 7. 295–295. 19 indexed citations

Braig, Friederike, Aneta Schieferdecker, Alexander Schulte, et al.. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget. 6(14). 12035–12047. 48 indexed citations

Knauf, Wolfgang, et al.. (2013). Response To 1st-Line Treatment With BR Or FCR In Patients With Chronic Lymphocytic Leukaemia: First Outcome Data From The German Prospective TLN Registry. Blood. 122(21). 4181–4181. 2 indexed citations

Dellas, Kathrin, Thomas Höhler, Thomas S. Reese, et al.. (2013). Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiation Oncology. 8(1). 90–90. 30 indexed citations

Rummel, Mathias, Christian Lerchenmüller, Richard Greil, et al.. (2012). Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).. Blood. 120(21). 2739–2739. 16 indexed citations

10.

Engel, Erik, et al.. (2010). Développement d'une stratégie de tourisme durable dans les aires protégées du Maroc. Tome 2: Manuel Méthodologique L’élaboration d’une stratégie, pas à pas. edoc Publication server (Humboldt University of Berlin). 4 indexed citations

11.

Engel, Erik, et al.. (2002). Exploring New Directions in Social Marketing. edoc Publication server (Humboldt University of Berlin). 5 indexed citations

12.

Engel, Erik, Wolfgang Tilgen, Christian Kennes, et al.. (1995). Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Research. 5(3). 195–195. 47 indexed citations

13.

Engel, Erik, et al.. (1993). Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.. PubMed. 3(2). 123–6. 5 indexed citations

14.

Engel, Erik, et al.. (1987). [Fosfomycin levels in the cerebrospinal fluid of patients with and without meningitis].. PubMed. 15(3). 98–102. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact